Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry

Salvatore Lucio Cutuli, Antonio Artigas, Roberto Fumagalli, Gianpaola Monti, Vito Marco Ranieri, Claudio Ronco, Massimo Antonelli, The EUPHAS 2 Collaborative Group, Riccardo Maviglia, Sandra Cicconi, Davide Silvestri, Giuseppe Bello, Alessandra Brendolan, Federico Nalesso, Gianluca Villa, Pasquale Piccinni, Erica Martin, Vincenzo Cantaluppi, Sergio Vesconi, Giampaolo CasellaEgidio Fasanella, Michele Debitonto, Gianmario Monza, Angelo Blasetti, Rosaria Coletta, Michele D’Ambrosio, Gilda Cinnella, Patrizia Murino, Eugenio Piscitelli, Gaetano Centonze, Marco Cucurachi, Giuseppe Altieri, Vincenzo Leonardo, Anna Sara Idra, Goffredo Del Rosso, Maria Polidoro, Nicola Stigliano, Giuseppe Pittella, Gianluca Paternoster, Giuseppe Pulito, Daniela Puscio, Diego Cingolani, Gabriele Falzetti, Pietro Vecchiarelli, Francesco Giunta, Francesco Forfori, Giacomo Castiglione, Stefano Greco, Carlo Capra, Luciano Crema, Leonor Tamayo, Cristina Urbano, Brunello Pezza, Nadia Zarrillo, Pasquale Di Monaco, Giuseppe Climaco, Pasquale De Negri, Pasqualina Modano, Riccardo Pagliarulo, Claudio Petrillo, Tania Stripoli, Roberto Oggioni, Laura Campiglia, Anna Rita Valletta, Manuela Lugano, Domenico Milella, Laura Micucci, Ursula Reist, Rolf Ensner, Christian Gianbarba, Lukas Brander, Rajib Paul, Rajesh Crawla, Sanjeev Jasujia, Rajesh Pande, Pratibha Dileep, Sankaran Sundar, Raju Ganesan, Sandeep Dewan, Vivek Nangia, Raj Kumar Mani, Omender Singh, Pracee Sathe, Gupta Sachin, Pradeep M. D’Costa, Samavedam Srivanas, Yogendra Pal Singh, Kent Doi, Fumika Taki, Ricard Ferrer Roca, Eduardo Romay Medina, Josè Gernacho, Francisco Martí, Alberto Martinez-Ruiz, Fernando Martinez-Sagasti, Rafael Zaragoza Crespo, Paola Torti, Valeria Terzi

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

© 2016, The Author(s). Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice. Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retrospective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracorporeal endotoxin removal by PMX-HP. Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal (44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % (60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. However, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission. Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal technique.
Original languageEnglish
Article number77
JournalAnnals of Intensive Care
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Dec 2016

Keywords

  • EAA
  • Extracorporeal endotoxin removal
  • Infection
  • Polymyxin-B hemoperfusion
  • Sepsis
  • Septic shock

Fingerprint Dive into the research topics of 'Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry'. Together they form a unique fingerprint.

Cite this